Pluristem jumps as FDA lifts suspension of Phase II drug trial

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

The FDA has lifted a clinical hold on the Phase II trials of Pluristem's (PSTI +9.3%) placenta-based IND 15038 cell treatment for intermittent claudication, which occurs when there is a reduction in the flow of blood to the leg muscles during exercise, causing pain.

The agency had halted the testing in June following "a serious allergic reaction" in one patient. Pluristem had suspended trials in Germany as well. (PR)